Nivalis Therapeutics Inc. (NASDAQ:NVLS) rose 2.8% during mid-day trading on Thursday . The company traded as high as $6.18 and last traded at $6.16, with a volume of 62,820 shares trading hands. The stock had previously closed at $5.99.

NVLS has been the subject of a number of recent research reports. Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, May 2nd. Zacks Investment Research upgraded Nivalis Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Tuesday, July 12th. Finally, HC Wainwright restated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 8th.

The firm’s 50 day moving average price is $5.14 and its 200 day moving average price is $4.67. The firm’s market capitalization is $96.12 million.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings results on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.03. Equities research analysts forecast that Nivalis Therapeutics Inc. will post ($2.29) earnings per share for the current year.

In related news, CMO David Malcom Rodman sold 5,950 shares of Nivalis Therapeutics stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $4.66, for a total transaction of $27,727.00. Following the completion of the sale, the chief marketing officer now owns 18,055 shares of the company’s stock, valued at $84,136.30. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.